Compared with chemotherapy and immunization, ibrutinib is more effective in treating elderly leukemia

Share This Post

The results of a multi-center phase III clinical trial showed that if elderly patients with chronic lymphocytic leukemia ( CLL ) are treated with a new targeted drug ibrutinib compared with the previously commonly effective regimen-bendamustine combined with rituximab The disease progression rate of mAb was significantly reduced, which also shows that rituximab combined with ibrutinib will not bring additional benefits over ibrutinib alone.

CLL is the most common leukocyte cancer in the elderly. In 2016 , the US FDA approved ibrutinib as the first-line treatment for CLL . Previous studies have shown that ibrutinib is more effective than another chemotherapeutic drug chlorambucil, but no studies have compared ibrutinib with bendamustine plus rituximab.

The trial enrolled 547 older patients with a median age of 71 years. 1/3 were randomly assigned to receive bendamustine Tingjia Li rituximab, 1/3 accepted by Lu rituximab for Nijia Li, 1/3 alone by Lu imatinib. The researchers followed up for a median of 38 months.

Compared with bendamustine plus rituximab ( 74 % at 2 years ), ibrutinib plus rituximab ( 88 % at 2 years ) and ibrutinib alone ( 2 At year, 87 %) patients had a longer progression-free survival rate (the primary endpoint of the study). However, the study found no difference in the overall survival rates of the three groups at 2 years.

Compared with receiving ibrutinib alone, adding rituximab to ibrutinib did not seem to improve the prognosis. Overall, patients responded well to all three treatment options. The overall response rate of patients receiving bendamustine plus rituximab was 81 %, and patients receiving ibrutinib plus rituximab to 93 % by Lu individual patients receiving imatinib therapy was 94 %.

Although the rate of complete eradication of leukemia using bendamustine plus rituximab was higher, this difference did not translate into better survival rates or lower relapse rates. So be more careful when choosing drugs.

However, ibrutinib is associated with significant side effects such as atrial fibrillation and abnormal heart rhythms that increase the risk of stroke and other cardiovascular diseases. The patient pays attention to monitoring the heart condition during use.

https://medicalxpress.com/news/2018-12-ibrutinib-outperforms-chemoimmunotherapy-older-patients.html

 

For details on leukemia treatment and second opinion, do call us at +91 96 1588 1588 or write to cancerfax@gmail.com.

Subscribe To Our Newsletter

Get updates and never miss a blog from Cancerfax

More To Explore

Risk of developing secondary tumors following CAR-T cell therapy is minimal - A Stanford Study
CAR T-Cell therapy

Risk of developing secondary tumors following CAR-T cell therapy is minimal – A Stanford Study

CAR-T cell therapy, a groundbreaking cancer treatment, carries a risk of developing secondary tumors. This occurs due to the therapy’s potential to cause genetic mutations or alter the immune system’s regulation. Secondary malignancies can arise from these changes, presenting a significant long-term risk for patients. Continuous monitoring and research are crucial to understanding and mitigating these risks, ensuring safer outcomes for those undergoing CAR-T cell therapy.

Seattle Children's Hospital to Start CAR T-Cell Clinical Trial for Pediatric Lupus Patients
CAR T-Cell therapy

Seattle Children’s Hospital to Start CAR T-Cell Clinical Trial for Pediatric Lupus Patients

Seattle Children’s Hospital is launching a groundbreaking CAR T-cell clinical trial for pediatric lupus patients. This innovative approach harnesses the body’s immune cells to target and eliminate lupus-affected cells, offering new hope for young patients with this autoimmune disorder. The trial represents a significant advancement in lupus treatment, aiming to improve outcomes and reduce long-term complications for children suffering from this challenging condition.

Need help? Our team is ready to assist you.

We wish a speedy recovery of your dear and near one.

Start chat
We Are Online! Chat With Us!
Scan the code
Hello,

Welcome to CancerFax !

CancerFax is a pioneering platform dedicated to connecting individuals facing advanced-stage cancer with groundbreaking cell therapies like CAR T-Cell therapy, TIL therapy, and clinical trials worldwide.

Let us know what we can do for you.

1) Cancer treatment abroad?
2) CAR T-Cell therapy
3) Cancer vaccine
4) Online video consultation
5) Proton therapy